Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody.
Most forms of chronic pain are inadequately treated by present therapeutic options. Compelling evidence has accumulated, demonstrating that Nerve Growth Factor (NGF) is a key modulator of inflammatory and nociceptive responses, and is a promising target for the treatment of human pathologies linked...
Guardado en:
Autores principales: | Sonia Covaceuszach, Sara Marinelli, Ivet Krastanova, Gabriele Ugolini, Flaminia Pavone, Doriano Lamba, Antonino Cattaneo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/863bba9b7db841b1a0914d87b29bdf05 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intranasal "painless" human Nerve Growth Factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in App X PS1 mice.
por: Simona Capsoni, et al.
Publicado: (2012) -
The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes.
por: Sara Marinelli, et al.
Publicado: (2012) -
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
por: Pascal Gasser, et al.
Publicado: (2020) -
Therapeutic effects of anti-HMGB1 monoclonal antibody on pilocarpine-induced status epilepticus in mice
por: Li Fu, et al.
Publicado: (2017) -
The Road to Toxin-Targeted Therapeutic Antibodies
por: Thomas R. Kozel
Publicado: (2014)